Congress Will Look To “Hesitant” FDA To Regulate Biosimilars – Former HHS Deputy
This article was originally published in The Pink Sheet Daily
Executive Summary
Follow-on biologics, and their eventual road to approval, were weighty discussion topics on the opening day of the BIO CEO conference.